Log in to save to my catalogue

Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients w...

Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients w...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2348098027

Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial

About this item

Full title

Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial

Publisher

United States: Public Library of Science

Journal title

PloS one, 2020-01, Vol.15 (1), p.e0228004-e0228004

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

Type 2 diabetes and dyslipidemia are diseases that collectively increase the risk of patients developing cardiovascular complications. Several incretin-based drugs are reported to improve lipid metabolism, and one of these medications, anagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that has been shown to decrease serum triglyceride and l...

Alternative Titles

Full title

Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_2348098027

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2348098027

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0228004

How to access this item